Drug Development

Eli Lily Wins Court Battle; Genzyme Appoints COO; And More.

As the industry continues to evolve, do we know where we're headed?

Laboratory personnel share interesting tales as well as stories of unexpected tails.

The authors examined the disintegration and dissolution profiles of propranolol and rofecoxib tablets overencapsulated with standard hard-gelatin capsules and with capsules specifically designed for double-blind clinical trials.

As demand for global vaccine development and production grows, all eyes are turning to Asia.

Interphex Showcase 2010.

The BIO convention, and healthcare reform, could re-energize biotech.

The authors describe the origins of single-use components and explain their application to aseptic processes. They also show how disposable devices have changed over time and offer a glimpse of the future.

Growth in the market for monoclonal antibodies, recombinant proteins, and vaccines creates new opportunities for drug companies and suppliers.

Biotechnology company Genzyme reported that FDA notified the company that it intends to take enforcement action to ensure that products are made in compliance with good manufacturing practice (GMP) regulations.

Pfizer Invests In Nodality; SOCMA Approves New Members; And More.

Merck Ends Partnership With Dynavax; PhRMA Elects Officers; And More.

Abbott Agrees to Acquire Facet Biotech; FDA Issues Black-Box Warning For Plavix; and More.

Continuous manufacturing could bring the pharmaceutical industry advantages such as improved product quality, easy scale-up, flexibility, and short cycle times. But how can a company switch from batch to continuous manufacturing?

Exelixis And XenoPort Announce Job Cuts; GSK Dedicates India Facility; And More.

Astellas Pharma Makes Bid for OSI Pharmaceuticals; Ringo Retiring From Pfizer; And More.

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Pre-Interphex 2010 Product Releases.

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Brief pharmaceutical news items for March 2010.

Analysis of the opportunities and challenges in the biosimilars market.

From last-minute product inserts to putting out fires, close calls are a common occurrence.

It's time to maintain a thorough traceable excipient trail.

If both sides of the aisle don't agree on even mild healthcare reform soon, the bill could die out.

The second annual Pharmaceutical Technology Bioprocessing Survey offers a snapshot of the industry following 2009's megamergers.